WuXi Biologics (Cayman) revenue and financials
$56.70Change from previous close: −2.07%Absolute change: −$1.20
In the fiscal year ended December 2025, WuXi Biologics (Cayman) reported revenue of ¥21.79B (+16.68% year over year). Net income was ¥4.91B, a net margin of 22.5%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +16.68%
- 2025 vs 2024
- Net income growth
- +46.25%
- 2025 vs 2024
- Net margin
- 22.5%
- 2024: 18.0%
Financial data
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | 63,697 | 56,977 | 56,576 | 49,564 | 44,033 |
| Current assets | 28,135 | 23,573 | 21,198 | 18,470 | 19,530 |
| Cash and equivalents | 9,214 | 8,279 | 9,670 | 6,395 | 9,003 |
| Short-term investments | 5,587 | 1,907 | 340 | 304 | 1,148 |
| Receivables | 8,896 | 6,374 | 6,675 | 5,775 | 4,181 |
| Inventory | 1,381 | 1,522 | 1,766 | 2,281 | 1,687 |
| Net property, plant and equipment | 29,754 | 28,435 | 29,939 | 25,916 | 19,756 |
| Goodwill | 1,530 | 1,530 | 1,530 | 1,530 | 1,530 |
| Other intangible assets | 467 | 442 | 512 | 549 | 601 |
| Long-term investments | 3,203 | 2,400 | 2,934 | 2,709 | 2,203 |
| Current liabilities | 8,308 | 8,621 | 7,636 | 9,319 | 8,256 |
| Accounts payable | 1,092 | 747 | 833 | 1,221 | 618 |
| Long-term debt | 169 | 201 | 1,571 | 1,462 | 641 |
| Total debt | 3,104 | 4,940 | 4,561 | 4,422 | — |
| Total liabilities | 10,657 | 11,500 | 12,558 | 13,351 | 11,326 |
| Total equity (incl. minority) | 53,039 | 45,478 | 44,018 | 36,213 | 32,706 |
| Retained earnings | 23,242 | 18,334 | 14,978 | 11,578 | 7,158 |
| Minority interest | 5,791 | 3,658 | 3,686 | 1,166 | 428 |